In 1945, a Goan entrepreneur Mr. Govind Ramnath Kare, who was in the business of wholesale and retail trade of pharmaceuticals, started a firm which he named Indo Continental Trading Company. The principal business of this firm was to import pharmaceutical formulations from Europe and distribute them in Western India. However in 1947, after India became independent, the new Government in its bid to encourage indigenous manufacturing of medicines banned import of several formulations. Mr. G.R. Kare instead of being discouraged, decided to venture into manufacturing of pharmaceuticals. Accordingly, on 23rd August 1947, a week after India's independence, a new Company was founded with the intent to manufacture and sell pharmaceutical formulations. Thus Indo Continental Trading Company became Indoco Remedies Limited. The manufacturing operations were started in a small house in Thane near Mumbai. However in this early period, the Company suffered a severe set-back. After Indian independence, the Portuguese Government in Goa sealed the border between Goa and India and Mr. Kare was unable to travel to Mumbai very often. In 1963, two years after Goa's independence, Mr. Suresh Kare, son of Mr. G.R. Kare came to Mumbai and took over as Managing Director of the then sick unit. Under the stewardship of Mr. Suresh Kare, Indoco never looked back. From a meager turnover of Rs. 1 Million and a total employee strength of around 50 in 1969, the Company has grown by leaps and bounds. Indoco now has an estimated turnover of Rs. 1.81 Billion for the year 2003-04 and is over 1750 employees strong. 2005 -Indoco Remedies enters into an Agency Agreement with SRU 2006 - Indoco Remedies mulls to enter US mkt. - Indoco Remedies secures US FDA approvals. - Board has proposed a dividend of 62.5%. 2007 - Mr. J. B. Salian has been appointed the Secretary of the Company. - Board has proposed a dividend of 65% . 2008 - Board has recommended a dividend of Rs 5.00 per share. - IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award. - First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA. 2009 - Board has decided to declare a final dividend of Rs 2.00 per equity share. - UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant. - Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area. 2010 - The Company has signed an agreement with Aspen Pharmacare, South Africa for supply of ophthalmic products. - Board has recommended a payment of divided of Rs. 7.00 per equity share. - Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia. 2011 - Board has recommended a dividend of Rs. 8/- per equity share. - Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations. 2012 - Indoco Remed - Enters into a strategic business alliance with DSM Pharmaceutical Products (DPP) NV. - Mr. Sunil Joshi has been appointed as Company Secretary & Compliance Officer of the Company. - Indoco announced the signing of an agreement with DSM, a _ 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO. -Company has splits its Face value of Shares from Rs 10 to Rs 2 -Indoco Remedies has given the Bonus in the Ratio of 1:2 2013 -Indoco Remedies Ltd. has received the approval from United States Food & Drug Administration (USFDA) to manufacture and market GLIMEPIRIDE 1mg, 2mg & 4mg tablets. -Indoco Remedia Ltd. has recommended payment of dividend of Rs.1.10 per equity share on the face value of Rs. 2/- each i.e. 55% for financial year 2012-13. 2014 -US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa. -IDMA Best Patent Award for Tazarotene & Adapalene. -Indoco Remedies Ltd. has Certificate of Good Manufacturing Practice (GMP) Compliance of a Manufacturer. 2015 - Indoco wins IDMA Patent Appreciation Award for Betaxolol - Indoco acquires Piramal's Clinical Research Division 2016 - Indoco acquires Manufacturing plant at Baddi - Indoco Honoured with the IDMA Best Patent Award for Three International Patents - Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category 2017 -Indoco receives the Express Pharma Export Excellence Award 2017 -Indoco receives UKMHRA approval for solid dosages Plant I in Goa -Indoco receives the IDMA Best Patent Award for four API Process Patents -Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO) 2018 -Indoco commissions For New API manufacturing facility at Patalganga -Indoco's Goa Plant II & III clears USFDA inspection -Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection -Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan -Indoco receives the IDMA Best Indian Patent Award for five API Process Patents -Indoco's Goa plant III receives EU GMP certification 2019 -Indoco successfully completes UK-MHRA inspection at Goa Plant II -Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops -Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent -Indoco's new solid dosages facility at Baddi receives UK-MHRA approval -Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection 2020 -Indoco wins major tenders in Germany for Allopurinol Tablets -Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg -Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents Diclofenac & Quetiapine -Indoco receives USFDA approval for Succinylcholine Chloride Injection USP -Indoco receives USFDA approval for Olanzapine Tablets 2021 -Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals 2022 -Indoco Remedies to acquire stake in Kanakal Wind Energy. -Indoco Remedies receives USFDA approval for Lacosamide Injection USP. -Indoco Remedies receives USFDA approval for Lacosamide Tablets. 2023 -Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets. -Indoco acquires 85 % equity stake in US based FPP Holding Company, LLC. -Indoco receives EIR for its manufacturing facility in Goa (Plant I). 2024 -Indoco enters into a strategic distribution partnership with Clarity Pharma, UK. -Indoco Remedies receives final ANDA approval from USFDA for Varenicline Tablets, 0.5 mg and 1 mg -Indoco Remedies receives final ANDA approval from USFDA for Pregabalin capsules. -Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets. -USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations.